Advertisement

Gastroesophageal Reflux and Prokinetics

  • Mário C. Vieira
Chapter

Abstract

Prokinetic agents have been widely employed in pediatric patients in order to reduce the symptoms of GERD. These drugs seem to enhance lower esophageal sphincter (LES) tone, to improve esophageal clearance, and to increase gastric motility thus increasing emptying of gastric contents.

Cisapride was probably the best studied prokinetic agent in children; however, it was taken off the market in the 2000s by the European and American authorities owing to its cardiac side effects. Other agents such as metoclopramide and domperidone have been evaluated, but a high incidence of adverse effects including drowsiness, restlessness, and extrapyramidal reactions has been reported. Bethanechol, a direct-acting cholinergic agonist, has been evaluated in a few studies and also has uncertain efficacy and a high incidence of adverse effects in children with GERD. Other prokinetic molecules including mosapride, itopride, and prucalopride have not been studied or have been insufficiently tested in children. Baclofen, used to treat patients with neurological impairment, is a γ-aminobutyric acid receptor agonist that was shown to be effective in reducing the number of transient lower esophageal sphincter relaxations (TLSERs) and acid GER as well as to accelerate gastric emptying. However, data on baclofen in pediatric GERD are very limited, and the high incidence of adverse events does not justify its widespread use. Other agents acting on TLSERs such as arbaclofen and lesogaberan have been evaluated in adult patients, but studies in children are lacking.

Overall, although the prokinetic concept is attractive, no effective and safe drug is currently available. Furthermore, all agents have a high incidence of adverse effects that outweigh the benefits achieved with their use.

Keywords

Gastroesophageal reflux disease Children Pediatrics Drug therapy Prokinetic Cisapride Domperidone Metoclopramide Bethanechol Baclofen 

References

  1. 1.
    Bredenoord AJ, Weusten BLAM, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut. 2006;55:313–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995;109(2):601–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Armstrong D. The clinical usefulness of prokinetic agents in gastrooesophageal reflux disease. In: Lundell L, editor. Guidelines for the management of symptomatic gastro-oesophageal reflux disease. London: Science Press; 1998. p. 45–54.Google Scholar
  4. 4.
    Chicella MF, Batres LA, Heesters MS, Dice JE. Prokinetic drug therapy in children: a review of current options. Ann Pharmacother. 2005;39(4):706–11.CrossRefPubMedGoogle Scholar
  5. 5.
    McCallum RW, Kline MM, Curry N, Sturdevant RA. Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients. Gastroenterology. 1975;68(5 Pt 1):1114–8.PubMedGoogle Scholar
  6. 6.
    Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics. 2006;118:746–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Craig WR, Hanlon-Dearman A, Sinclair C, Taback S, Moffatt M. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev. 2004;4:CD003502.Google Scholar
  8. 8.
    Hyams JS, Leichtner AM, Zamett LO, Walters JK. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1986;5:716–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Machida HM, Forbes DA, Gall DG, Scott RB. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr. 1988;112(3):483–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Madani S, Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol. 1997;24(2):79–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Putnam PE, Orenstein SR, Wessel HB, Stowe RM. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr. 1992;121:983–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Paturi B, Ryan RM, Michienzi KA, Lakshminrusimha S. Galactorrhea with metoclopramide use in the neonatal unit. J Perinatol. 2009;29:391–2.CrossRefPubMedGoogle Scholar
  13. 13.
    Mejia NI, Jankovic J. Metoclopramide induced tardive dyskinesia in an infant. Mov Disord. 2005;20:86–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Dunne CE, Bushee JL, Argikar UA. Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes. Drug Metab Pharmacokinet. 2013;28(6):453–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Shafrir Y, Levy Y, Beharab A, Nitzam M, Steinherz R. Acute dystonic reaction to bethanechol – a direct acetylcholine receptor agonist. Dev Med Child Neurol. 1986;28:646–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr. 1980;96:321–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Levi P, Marmo F, Saluzzo C, Dell’Olio D, Ansaldi N, Giuliani L, Guardamagna O, Mostert M, Ponzone A. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta. 1985;40:349–59.PubMedGoogle Scholar
  18. 18.
    Dubin A, Kikkert M, Mirmiran M, Ariagno R. Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics. 2001;107(6):1313–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Ariagno RL, Kikkert MA, Mirmiran M, Conrad C, Baldwin RB. Cisapride decreases gastroesophageal reflux in preterm infants. Pediatrics. 2001 Apr;107(4):E58.CrossRefPubMedGoogle Scholar
  21. 21.
    Bernardini S, Semama DS, Huet F, Sgro C, Gouyon JB. Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed. 1997;77(3):F241–3.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Corvaglia L, Faldella G, Rotatori R, Lanari M, Capretti MG, Salvioli GP. Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants. Cardiovasc Drugs Ther. 2004;18(5):371–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Maclennan S, Augood C, Cash-Gibson L, Logan S, Gilbert RE. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2010;4:CD002300.Google Scholar
  24. 24.
    Augood C, MacLennan S, Gilbert R, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2003;4:CD002300.Google Scholar
  25. 25.
    Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol. 2005;59(6):725–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M, Notarbartolo A. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo. Scand J Gastroenterol. 1994;29(4):300–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Scott B. Question 2. How effective is domperidone at reducing symptoms of gastro-oesophageal reflux in infants? Arch Dis Child. 2012;97(8):752–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Clara R. Chronic regurgitation and vomiting treated with domperidone. A multicenter evaluation. Acta Paediatr Belg. 1979;32:203–7.Google Scholar
  29. 29.
    Bines JE, Quinlan J, Treves S, et al. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1992;14:400–5.CrossRefPubMedGoogle Scholar
  30. 30.
    De Loore L, Van Ravenstayn H. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgrad Med J. 1979;55(Suppl 1):40–2.PubMedGoogle Scholar
  31. 31.
    Sol P, Pelet B. Extrapyramidal reaction due to domperidone. Lancet. 1980;1:802.CrossRefGoogle Scholar
  32. 32.
    Shafrir Y, Levy Y. Oculogyric crises due to domperidone therapy. Helv Paediatr Acta. 1985;40:95.PubMedGoogle Scholar
  33. 33.
    Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26:720–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Hondeghem LM. Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death. Acta Cardiol. 2011;66:421–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5:257–62.CrossRefPubMedGoogle Scholar
  36. 36.
    Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153:663–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Günlemez A, Babaoglu A, Artsoy AE, Tûrker G, Gökalp AS. Effect of domperidone on the QTc interval in premature infants. J Perinatol. 2010;30:50–3.CrossRefPubMedGoogle Scholar
  38. 38.
    Vieira MC, Miyague NI, Van Steen K, Salvatore S, Vandenplas Y. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101:494–6.CrossRefPubMedGoogle Scholar
  39. 39.
    van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33:1003–14.CrossRefPubMedGoogle Scholar
  40. 40.
    Cucchiara S, Bortolotti M, Minella R, et al. Fasting and postprandial mechanisms of gastroesophageal reflux in children with gastroesophageal reflux disease. Dig Dis Sci. 1993;38:86–92.CrossRefPubMedGoogle Scholar
  41. 41.
    Kawahara H, Dent J, Davidson G. Mechanisms responsible for gastro gastroesophageal reflux in children. Gastroenterology. 1997;113:399–408.CrossRefPubMedGoogle Scholar
  42. 42.
    Werlin SL, Dodds WJ, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in children. J Pediatr. 1980;97:244–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Omari T. Gastro-oesophageal reflux disease in infants and children: new insights, developments and old chestnuts. J Pediatr Gastroenterol Nutr. 2005;41(suppl 1):S21–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2002;35:119–36.CrossRefPubMedGoogle Scholar
  45. 45.
    Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50(1):19–24.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kawai M, Kawahara H, Hirayama S, et al. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2004;38:317–23.CrossRefPubMedGoogle Scholar
  47. 47.
    Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr. 2006;149:468–74.CrossRefPubMedGoogle Scholar
  48. 48.
    Vadlamudi NB, Hitch MC, Dimmitt RA, Thame KA. Baclofen for the treatment of pediatric GERD. J Pediatr Gastroenterol Nutr. 2013;57(6):808–12.CrossRefPubMedGoogle Scholar
  49. 49.
    Vakil NB, Huff FJ, Cundy KC. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease – insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther. 2013;38(2):107–17.CrossRefPubMedGoogle Scholar
  50. 50.
    Miner PB Jr, Silberg DG, Ruth M, Miller F, Pandolfino J. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. BMC Gastroenterol. 2014;14:188.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498–547.CrossRefPubMedGoogle Scholar
  52. 52.
    Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131(5):e1684–95.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Centro de Gastroenterologia PediátricaHospital Pequeno PríncipeCuritibaBrazil
  2. 2.Escola de MedicinaPontifícia Universidade Católica do Paraná (PUCPR)CuritibaBrazil

Personalised recommendations